ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1389

The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Abstract Number: 1390

Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort
Abstract Number: 1391

Inadequate Cardiovascular Disease Risk Screening and Preventative Treatment in Patients with Rheumatoid Arthritis
Abstract Number: 1392

Comparing Data on Rheumatoid Arthritis (RA) Disease Status Using Patient Reported Outcome Measures (PROMS) RAID/RAPID-3/Self-Reported DAS28 in Remote Electronic Monitoring During the COVID-19 Pandemic with Face-To-Face Clinical Evaluation (DAS28-CRP) Performed Pre-Pandemic
Abstract Number: 1393

Lung Involvement in Early Rheumatoid Arthritis, Interim Analysis of the FINDRA Prospective Study
Abstract Number: 1394

Identification of Joint Locations in an Early Rheumatoid Arthritis Cohort as a Characteristic of Disease Severity: DATA from the ERA-UCLouvain Brussels Cohort
Abstract Number: 1395

Comparative Safety of Janus Kinase Inhibitors and Tumor Necrosis Factor Inhibitors in Patients Undergoing Treatment for Rheumatoid Arthritis
Abstract Number: 1396

Risk of Hospitalized Infections in Older Elderly Rheumatoid Arthritis Patients Treated with Biological/Targeted Synthetic DMARDs: Evaluation Using Data from a Japanese Claims Database
Abstract Number: 1397

The Impact of Disease Activity on Patient-Reported Cognitive Dysfunction in Rheumatoid Arthritis
Abstract Number: 1398

Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 1399

Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Abstract Number: 1400

Machine Learning Identifies Molecular Phenotypes That Predict Incident Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1401

Relationship Between Disease Activity and Adverse Events of Interest in Patients with RA on Tofacitinib or TNF Inhibitors: Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Abstract Number: 1402

Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Abstract Number: 1403

Herpes Zoster in Rheumatoid Arthritis: Prospective Single University Center Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].